Literature DB >> 25445815

Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer.

Eva-Maria Surmann1, Anita Y Voigt, Sara Michel, Kathrin Bauer, Miriam Reuschenbach, Soldano Ferrone, Magnus von Knebel Doeberitz, Matthias Kloor.   

Abstract

Besides being expressed on professional antigen-presenting cells, HLA class II antigens are expressed on various tumors of non-lymphoid origin, including a subset of colorectal cancers (CRC). Information about the regulation of HLA class II antigen expression is important for a better understanding of their role in the interactions between tumor and immune cells. Whether lack of HLA class II antigen expression in tumors reflects the selective immune destruction of HLA class II antigen-expressing tumor cells is unknown. To address this question, we tested whether lack of HLA class II antigen expression in CRC was associated with immune cell infiltration. We selected microsatellite-unstable (MSI-H) CRC, because they show pronounced tumor antigen-specific immune responses and, in a subset of tumors, lack of HLA class II antigen expression due to mutations inactivating HLA class II-regulatory genes. We examined HLA class II antigen expression, mutations in regulatory genes, and CD4-positive T cell infiltration in 69 MSI-H CRC lesions. Mutations in RFX5, CIITA, and RFXAP were found in 13 (28.9%), 3 (6.7%), and 1 (2.2%) out of 45 HLA class II antigen-negative tumors. CD4-positive tumor-infiltrating lymphocyte counts were significantly higher in HLA class II antigen-negative tumors harboring mutations in HLA class II-regulatory genes (107.4 T cells per 0.25 mm(2)) compared to tumors without mutations (55.5 T cells per 0.25 mm(2), p = 0.008). Our results suggest that the outgrowth of tumor cells lacking HLA class II antigen expression due to mutations of regulatory genes is favored in an environment of dense CD4-positive T cell infiltration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25445815      PMCID: PMC8711774          DOI: 10.1007/s00262-014-1638-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  37 in total

1.  Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases.

Authors:  Noel F C C de Miranda; Danny Goudkade; Ekaterina S Jordanova; Carli M J Tops; Frederik J Hes; Hans F A Vasen; Tom van Wezel; Hans Morreau
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

2.  Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.

Authors:  N S Williams; V H Engelhard
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

3.  Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas.

Authors:  D C Bicknell; L Kaklamanis; R Hampson; W F Bodmer; P Karran
Journal:  Curr Biol       Date:  1996-12-01       Impact factor: 10.834

4.  Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.

Authors:  Sara Michel; Michael Linnebacher; Joshua Alcaniz; Maike Voss; Rudolf Wagner; Wolfgang Dippold; Christina Becker; Magnus von Knebel Doeberitz; Soldano Ferrone; Matthias Kloor
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

5.  Microsatellite instability in cancer of the proximal colon.

Authors:  S N Thibodeau; G Bren; D Schaid
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

Review 6.  Biological implications of HLA-DR expression in tumours.

Authors:  T Cabrera; F Ruiz-Cabello; F Garrido
Journal:  Scand J Immunol       Date:  1995-04       Impact factor: 3.487

Review 7.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

8.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis.

Authors:  Y Ionov; M A Peinado; S Malkhosyan; D Shibata; M Perucho
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

9.  Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases.

Authors:  A Buckowitz; H-P Knaebel; A Benner; H Bläker; J Gebert; P Kienle; M von Knebel Doeberitz; M Kloor
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

10.  High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability.

Authors:  S Michel; A Benner; M Tariverdian; N Wentzensen; P Hoefler; T Pommerencke; N Grabe; M von Knebel Doeberitz; M Kloor
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more
  18 in total

1.  High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.

Authors:  Jonas Janikovits; Meike Müller; Julia Krzykalla; Sandrina Körner; Fabian Echterdiek; Bernd Lahrmann; Niels Grabe; Martin Schneider; Axel Benner; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

2.  Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.

Authors:  Fabian Echterdiek; Jonas Janikovits; Laura Staffa; Meike Müller; Bernd Lahrmann; Monika Frühschütz; Benjamin Hartog; Nina Nelius; Axel Benner; Mirjam Tariverdian; Magnus von Knebel Doeberitz; Niels Grabe; Matthias Kloor
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

3.  Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Authors:  Ainhoa Arina; Theodore Karrison; Eva Galka; Karin Schreiber; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-11       Impact factor: 11.151

Review 4.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

5.  IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response.

Authors:  Guoping Ding; Liangjing Zhou; Tao Shen; Liping Cao
Journal:  Oncol Lett       Date:  2018-01-12       Impact factor: 2.967

Review 6.  Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.

Authors:  Adithya Balasubramanian; Thomas John; Marie-Liesse Asselin-Labat
Journal:  Biochem Soc Trans       Date:  2022-04-29       Impact factor: 4.919

Review 7.  Opportunities for immunotherapy in microsatellite instable colorectal cancer.

Authors:  Harm Westdorp; Felix L Fennemann; Robbert D A Weren; Tanya M Bisseling; Marjolijn J L Ligtenberg; Carl G Figdor; Gerty Schreibelt; Nicoline Hoogerbrugge; Florian Wimmers; I Jolanda M de Vries
Journal:  Cancer Immunol Immunother       Date:  2016-04-08       Impact factor: 6.968

Review 8.  CD4 and CD8 T lymphocyte interplay in controlling tumor growth.

Authors:  Dmitrij Ostroumov; Nora Fekete-Drimusz; Michael Saborowski; Florian Kühnel; Norman Woller
Journal:  Cell Mol Life Sci       Date:  2017-10-14       Impact factor: 9.261

Review 9.  HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.

Authors:  Per Anderson; Natalia Aptsiauri; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 22.096

10.  Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p.

Authors:  Guoping Ding; Liangjing Zhou; Yingming Qian; Mingnian Fu; Jian Chen; Jionghuang Chen; Jianyang Xiang; Zhengrong Wu; Guixing Jiang; Liping Cao
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.